COMPANY PROFILE // THE 014 REPORT
Century Therapeutics, Inc.
IPSC (Nasdaq)
Assembled from 4 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-09-09: a pattern of leadership change.
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2025-08-29 and 1 more time (last 24 months).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Century Therapeutics, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in Philadelphia, PA; listed as IPSC (Nasdaq).[source] It reported revenue of $109.2 million for the fiscal year ended 2025-12-31.[source] It has filed 110 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-17.[source] Its largest institutional holders on 13F filings are RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management, LLC, Versant Venture Management, LLC (as of 2026-06-30).[source] Seraphix flags 2 items from these records: 8-K Item 3.01 filed; 4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-09-09.[source]
- red0
- amber2
- info0
- RA CAPITAL MANAGEMENT, L.P.$43.5M
- TCG Crossover Management, LLC$43.4M
- Versant Venture Management, LLC$29.8M
- Deep Track Capital, LP$23.2M
- Commodore Capital LP$21.3M
- RTW INVESTMENTS, LP$21.3M
- Venrock Adviser, LLC$21.3M
- BlackRock, Inc.$19.8M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Carr Douglas · SVP Finance & Operations (Officer) · latest Form 4 2026-03-16 · filing · LinkedIn search
- Cowan Chad · Chief Scientific Officer (Officer) · latest Form 4 2026-03-13 · filing · LinkedIn search
- Farid Adrienne · Chief Operations Officer (Officer) · latest Form 4 2025-06-11 · filing · LinkedIn search
- Pfeiffenberger Brent · President and CEO (Director,Officer) · latest Form 4 2026-03-13 · filing · LinkedIn search
- Russotti Gregory · See Remarks (Officer) · latest Form 4 2026-03-16 · filing · LinkedIn search
- BUTITTA CYNTHIA M · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- Blackwell Kimberly · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- Carlo Rizzuto · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- JIMENEZ JOSEPH · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- Lee Han Myung · Director · latest Form 4 2025-12-11 · filing · LinkedIn search
- Quimi Daphne · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- Riva Alessandro · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Goodwin Procter LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-03-12
Links
- Official website (Wikidata or the SEC record)
- Wikidata
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001850119 | source |
| EIN | 84-2040295 | source |
| Business address (SEC) | 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- UroGen Pharma Ltd. · BUTITTA CYNTHIA M
- Autolus Therapeutics plc · BUTITTA CYNTHIA M
- Olema Oncology, Inc. · BUTITTA CYNTHIA M
- Monte Rosa Therapeutics, Inc. · Blackwell Kimberly
- PROCTER & GAMBLE Co · JIMENEZ JOSEPH
- General Motors Co · JIMENEZ JOSEPH
- Amylyx Pharmaceuticals, Inc. · Quimi Daphne
- BeOne Medicines Ltd. · Riva Alessandro
- BICYCLE THERAPEUTICS PLC · Riva Alessandro
- BIOMARIN PHARMACEUTICAL INC · Walbert Timothy P
- Sagimet Biosciences Inc. · Walbert Timothy P
- Mirum Pharmaceuticals, Inc. · Walbert Timothy P
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-11-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-03 filing 144 · SEC EDGAR
- 2026-10-02 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-09-14 filing 144 · SEC EDGAR
- 2026-09-14 filing 144 · SEC EDGAR
- 2026-09-09 officer change 8-K items 5.02,7.01,9.01 · SEC EDGAR
- 2026-09-08 filing 144 · SEC EDGAR
- 2026-08-12 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-08-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-06-16 officer change 8-K items 5.02 · SEC EDGAR
- 2026-06-12 filing 8-K items 5.03,5.07,9.01 · SEC EDGAR
- 2026-06-12 filing 144 · SEC EDGAR
- 2026-06-08 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-06-08 filing 144 · SEC EDGAR
- 2026-05-21 filing 424B7 · SEC EDGAR
- 2026-05-13 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-05-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-27 filing DEFA14A · SEC EDGAR
- 2026-04-27 filing Proxy statement · SEC EDGAR
- 2026-04-16 filing ARS · SEC EDGAR
- 2026-04-16 filing PRE 14A · SEC EDGAR
- 2026-03-26 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-03-26 filing 424B5 · SEC EDGAR
- 2026-03-12 filing 144 · SEC EDGAR
- 2026-03-12 filing S-8 · SEC EDGAR
- 2026-03-12 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-03-12 filing Annual report (10-K) · SEC EDGAR
- 2026-03-09 filing 144 · SEC EDGAR
- 2026-02-17 filing EFFECT · SEC EDGAR
170 earlier entries
- 2026-02-17 filing UPLOAD
- 2026-02-17 filing CORRESP
- 2026-02-05 filing S-3
- 2026-01-23 filing 8-K items 5.07,8.01
- 2026-01-12 filing 8-K items 7.01,9.01
- 2026-01-09 filing EFFECT
- 2026-01-08 filing 8-K items 1.01,3.02,7.01,9.01
- 2026-01-07 filing CORRESP
- 2026-01-05 filing S-3/A
- 2025-12-29 officer change 8-K items 5.02
- 2025-12-12 filing 8-K items 7.01,9.01
- 2025-12-11 insider First Form 3/4/5 on record for Lee Han Myung (Director)
- 2025-12-09 filing 144/A
- 2025-12-09 officer change 8-K items 5.02,7.01,9.01
- 2025-12-08 filing 144
- 2025-12-08 filing 144
- 2025-12-02 filing DEFA14A
- 2025-12-02 filing Proxy statement
- 2025-11-21 filing PRE 14A
- 2025-11-20 filing 144
- 2025-11-17 filing 144
- 2025-11-13 filing 8-K items 2.02,7.01,8.01,9.01
- 2025-11-13 filing Quarterly report (10-Q)
- 2025-09-22 insider First Form 3/4/5 on record for Cowan Chad (Chief Scientific Officer)
- 2025-09-08 filing 144
- 2025-09-08 filing 144
- 2025-08-29 filing 8-K items 3.01
- 2025-08-18 filing 144
- 2025-08-14 filing Quarterly report (10-Q)
- 2025-08-14 officer change 8-K items 2.02,5.02,7.01,9.01
- 2025-07-14 filing UPLOAD
- 2025-07-10 filing S-3
- 2025-07-07 officer change 8-K items 2.05,5.02
- 2025-06-16 filing 8-K items 5.07
- 2025-06-16 insider First Form 3/4/5 on record for BUTITTA CYNTHIA M (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Blackwell Kimberly (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Carlo Rizzuto (Director)
- 2025-06-16 insider First Form 3/4/5 on record for JIMENEZ JOSEPH (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Quimi Daphne (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Riva Alessandro (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Walbert Timothy P (Director)
- 2025-06-11 insider First Form 3/4/5 on record for Russotti Gregory (See Remarks)
- 2025-06-09 filing 144
- 2025-06-09 filing 144
- 2025-06-09 filing 144
- 2025-05-20 insider First Form 3/4/5 on record for Pfeiffenberger Brent (President and CEO)
- 2025-05-16 filing 144
- 2025-05-15 filing Quarterly report (10-Q)
- 2025-05-15 filing 8-K items 2.02,7.01,9.01
- 2025-05-07 insider First Form 3/4/5 on record for Carr Douglas (SVP Finance & Operations)
- 2025-05-07 insider First Form 3/4/5 on record for Farid Adrienne (Chief Operations Officer)
- 2025-05-05 filing 144
- 2025-04-22 filing ARS
- 2025-04-22 filing DEFA14A
- 2025-04-22 filing Proxy statement
- 2025-03-20 filing S-8
- 2025-03-19 filing 8-K items 2.02,7.01,9.01
- 2025-03-19 filing Annual report (10-K)
- 2025-03-10 filing 144
- 2025-03-10 filing 144
- 2025-03-10 filing 144
- 2025-02-28 filing 8-K items 3.01
- 2025-02-18 filing 144
- 2025-02-03 filing 144
- 2025-01-13 filing 8-K items 2.02,7.01,9.01
- 2024-12-13 filing 8-K items 1.02
- 2024-11-05 filing 8-K items 2.02,8.01,9.01
- 2024-11-05 filing Quarterly report (10-Q)
- 2024-11-04 filing 144
- 2024-09-26 officer change 8-K items 5.02
- 2024-08-08 filing 8-K items 2.02,7.01,9.01
- 2024-08-08 filing Quarterly report (10-Q)
- 2024-08-05 filing 144
- 2024-07-26 filing 144
- 2024-07-24 filing 144
- 2024-07-23 filing 144
- 2024-07-08 filing 8-K items 8.01,9.01
- 2024-06-26 filing EFFECT
- 2024-06-26 filing 8-K/A items 9.01
- 2024-06-26 filing 424B3
- 2024-06-25 filing CORRESP
- 2024-06-24 filing UPLOAD
- 2024-06-24 filing 8-K items 5.07
- 2024-06-20 filing 144
- 2024-06-18 filing S-3
- 2024-06-05 filing 144
- 2024-06-03 filing 8-K items 8.01,9.01
- 2024-05-22 filing 424B3
- 2024-05-21 filing EFFECT
- 2024-05-20 filing 144
- 2024-05-17 filing CORRESP
- 2024-05-17 filing UPLOAD
- 2024-05-15 filing S-3
- 2024-05-09 filing 8-K items 2.02,9.01
- 2024-05-09 filing Quarterly report (10-Q)
- 2024-05-06 filing 144
- 2024-05-03 filing 144
- 2024-04-26 filing ARS
- 2024-04-26 filing DEFA14A
- 2024-04-26 filing Proxy statement
- 2024-04-22 filing 144
- 2024-04-16 filing PRE 14A
- 2024-04-11 filing 8-K items 2.01,3.02,7.01,9.01
- 2024-04-11 filing 8-K items 8.01,9.01
- 2024-04-09 filing 8-K items 8.01,9.01
- 2024-04-08 filing SC 13D/A
- 2024-03-20 filing 144
- 2024-03-18 filing 144
- 2024-03-15 filing 144
- 2024-03-14 filing S-8
- 2024-03-14 filing 8-K items 2.02,7.01,9.01
- 2024-03-14 filing Annual report (10-K)
- 2024-03-07 filing 144
- 2024-03-07 filing 144
- 2024-03-06 filing 144
- 2024-03-06 filing 144
- 2024-02-21 filing 144/A
- 2024-02-16 filing 144
- 2024-02-06 filing 144
- 2024-02-06 filing 144
- 2024-02-05 filing 144
- 2024-02-05 filing 144
- 2024-01-19 officer change 8-K items 5.02
- 2023-12-11 filing 8-K items 8.01,9.01
- 2023-12-06 filing 8-K items 8.01,9.01
- 2023-11-14 officer change 8-K items 5.02
- 2023-11-09 filing 8-K items 2.02,7.01,9.01
- 2023-11-09 filing Quarterly report (10-Q)
- 2023-10-03 filing 8-K items 8.01,9.01
- 2023-08-09 filing 8-K items 2.02,7.01,9.01
- 2023-08-09 filing Quarterly report (10-Q)
- 2023-06-29 filing 8-K items 5.07
- 2023-05-11 filing 8-K items 2.02,9.01
- 2023-05-11 filing Quarterly report (10-Q)
- 2023-05-05 officer change 8-K/A items 5.02,9.01
- 2023-05-05 filing 8-K items 1.02
- 2023-04-28 filing ARS
- 2023-04-28 filing DEFA14A
- 2023-04-28 filing Proxy statement
- 2023-04-17 officer change 8-K items 5.02,9.01
- 2023-03-23 filing 144
- 2023-03-22 filing 144
- 2023-03-21 filing 144
- 2023-03-20 filing 8-K items 7.01
- 2023-03-17 filing S-8
- 2023-03-16 filing 8-K items 2.02,9.01
- 2023-03-16 filing Annual report (10-K)
- 2023-03-13 filing 8-K items 7.01
- 2023-01-09 filing 8-K items 7.01,8.01,9.01
- 2022-11-30 filing 8-K items 7.01,9.01
- 2022-11-10 filing 8-K items 7.01,9.01
- 2022-11-10 filing 8-K items 2.02,9.01
- 2022-11-10 filing Quarterly report (10-Q)
- 2022-10-11 filing SC 13D/A
- 2022-10-03 officer change 8-K items 5.02
- 2022-09-08 filing 8-K items 7.01,9.01
- 2022-08-25 filing 8-K items 8.01,9.01
- 2022-08-11 filing 8-K items 2.02,9.01
- 2022-08-11 filing Quarterly report (10-Q)
- 2022-07-13 filing EFFECT
- 2022-07-11 filing CORRESP
- 2022-07-08 filing UPLOAD
- 2022-07-01 filing 8-K items 1.01,9.01
- 2022-07-01 filing S-3
- 2022-06-13 filing 8-K items 7.01,9.01
- 2022-06-10 filing 8-K items 5.07
- 2022-05-16 filing Quarterly report (10-Q)
- 2022-05-16 filing 8-K items 2.02,9.01
- 2022-05-10 filing 8-K items 8.01,9.01
- 2022-04-21 filing DEFA14A
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-12 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-12 (within 30 days) 10-Q filed
- 2026-10-07 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-10-02 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-15 (older) Form 5500 received for plan year ending 2026-03-31 (plan no. 501)
- 2026-09-09 (older) 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-12 (older) 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-12 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:IPSC The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1850119 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | IPSC / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 842040295 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001850119 | SEC EDGAR / IRS |
| CUSIP | 15673T100 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001850119 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $109,164,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-20 11:15 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$9,580,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 11:15 UTC | Report an error |
| Total assets (at 2025-12-31) | $223,704,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 11:15 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $158,936,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 11:15 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $61,853,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 11:15 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 11:15 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 11:15 UTC | Report an error |
| State of incorporation | DE | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 11:15 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 11:15 UTC | Report an error |
| Business address | 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 11:15 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 11:15 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$103,876,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 11:15 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $848,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 11:15 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $43,565,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 11:15 UTC | Report an error |
| Form D total offering amount (D filed 2021-03-15) | $160,000,000 | 2021-03-15 | D | as filed | 2026-11-20 11:15 UTC | Report an error |
| Form D total amount sold (D filed 2021-03-15) | $0 | 2021-03-15 | D | as filed | 2026-11-20 11:15 UTC | Report an error |
| Form D industry group | Other Health Care | 2021-03-15 | D | as filed | 2026-11-20 11:15 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2021-03-15 | D | as filed | 2026-11-20 11:15 UTC | Report an error |
| Form D date of first sale | 2021-02-25 | 2021-03-15 | D | as filed | 2026-11-20 11:15 UTC | Report an error |
| Plan (welfare, plan no. 501) | CENTURY THERAPEUTICS, INC. EMPLOYEE HEALTH AND WELFARE BENEFITS PLAN: 83 participants | 2026-03-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-20 11:15 UTC | Report an error |
| Plan (pension, plan no. 001) | CENTURY THERAPEUTICS, INC. 401(K) PROFIT SHARING PLAN: 193 participants, assets $22,129,839 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-20 11:15 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001104659-26-125813
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$23,453,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125813 | 2026-11-20 11:15 UTC | Report an error |
| Cash and cash equivalents | $45,016,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0001104659-26-125813 | 2026-11-20 11:15 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-12 Filing 10-Q filed
- 2026-10-07 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-10-02 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-15 Filing Form 5500 received for plan year ending 2026-03-31 (plan no. 501)
- 2026-09-09 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-12 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-12 Filing 10-Q filed
- 2026-06-18 Record earliest certified decision date in the file
- 2026-06-18 Record latest certified decision date in the file
- 2026-06-16 Filing 8-K filed: Item 5.02 officer or director change
- 2026-06-12 Filing 8-K filed: Item 5.03 charter or bylaw amendment; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-06-08 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-05-21 Filing 424B7 filed
- 2026-05-13 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-13 Filing 10-Q filed
- 2026-04-27 Filing DEFA14A filed
- 2026-04-27 Filing DEF 14A filed (FORM DEF 14A)
- 2026-04-16 Filing ARS filed
- 2026-04-16 Filing PRE 14A filed
- 2026-03-26 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-03-26 Filing 424B5 filed
- 2026-03-12 Filing S-8 filed (FORM S-8)
- 2026-03-12 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-03-12 Filing 10-K filed
6 earlier entries
- 2026-02-17 Filing EFFECT filed
- 2026-02-17 Filing UPLOAD filed
- 2026-02-17 Filing CORRESP filed
- 2026-02-05 Filing S-3 filed
- 2021-04-01 Record plan effective date: CENTURY THERAPEUTICS, INC. EMPLOYEE HEALTH AND WELFARE BENEFITS PLAN
- 2019-04-01 Record plan effective date: CENTURY THERAPEUTICS, INC. 401(K) PROFIT SHARING PLAN
8-K item text, as filed (excerpts)
- 2026-11-12 8-K Item 2.02
Results of Operations and Financial Condition On November 12, 2026, Century Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the… the 8-K · retrieved 2026-11-20 11:15 UTC - 2026-10-02 8-K Item 7.01
Regulation FD Disclosure On October 2, 2026, Century Therapeutics, Inc. (the “Company”) issued a press release announcing that nonclinical data from the Company’s iPSC-derived cell therapy platform was presented at the European Association for the Study of Diabetes (“EASD”) held on October 2, 2026 in Milan, Italy. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to… the 8-K · retrieved 2026-11-20 11:15 UTC - 2026-10-02 8-K Item 8.01
Other Events A copy of the slides presented by the Company at EASD is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2. the 8-K · retrieved 2026-11-20 11:15 UTC - 2026-09-09 8-K Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 9, 2026, the Board of Directors (the “Board”) of Century Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from six to seven directors and appointed Mr. Joseph Truitt as a member of the Board, effective as of September 9, 2026 (the “Effective Date”). Mr. Truitt will serve as a Class I director with a term expiring at the 2028 Annual Meeting of Stockholders, or until his successor is duly elected and qualified or until his earlier… the 8-K · retrieved 2026-11-20 11:15 UTC - 2026-09-09 8-K Item 7.01
Regulation FD Disclosure On September 9, 2026, the Company issued a press release announcing the appointment to the Board as discussed above. The full text of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth… the 8-K · retrieved 2026-11-20 11:15 UTC - 2026-08-12 8-K Item 2.02
Results of Operations and Financial Condition On August 12, 2026, Century Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the… the 8-K · retrieved 2026-11-20 11:15 UTC - 2026-08-12 8-K Item 7.01
Regulation FD Disclosure On August 12, 2026, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time. The information contained in this Item 7.01 (including Exhibit 99.2) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be… the 8-K · retrieved 2026-11-20 11:15 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA RCRA hazardous waste (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCENTURY THERAPEUTICS INC · exact legal name · sx:rcra:MAR000655688 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | $43,498,354 | 2026-06-30 | SEC 13F filing | 2026-11-20 11:15 UTC | Report an error |
| 2 | TCG Crossover Management, LLC | $43,401,690 | 2026-06-30 | SEC 13F filing | 2026-11-20 11:15 UTC | Report an error |
| 3 | Versant Venture Management, LLC | $29,806,967 | 2026-06-30 | SEC 13F filing | 2026-11-20 11:15 UTC | Report an error |
| 4 | Deep Track Capital, LP | $23,183,480 | 2026-06-30 | SEC 13F filing | 2026-11-20 11:15 UTC | Report an error |
| 5 | Commodore Capital LP | $21,304,347 | 2026-06-30 | SEC 13F filing | 2026-11-20 11:15 UTC | Report an error |
| 6 | RTW INVESTMENTS, LP | $21,304,347 | 2026-06-30 | SEC 13F filing | 2026-11-20 11:15 UTC | Report an error |
| 7 | Venrock Adviser, LLC | $21,304,347 | 2026-06-30 | SEC 13F filing | 2026-11-20 11:15 UTC | Report an error |
| 8 | BlackRock, Inc. | $19,824,831 | 2026-06-30 | SEC 13F filing | 2026-11-20 11:15 UTC | Report an error |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | $13,974,016 | 2026-06-30 | SEC 13F filing | 2026-11-20 11:15 UTC | Report an error |
| 10 | Balyasny Asset Management L.P. | $13,531,213 | 2026-06-30 | SEC 13F filing | 2026-11-20 11:15 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
DOL H-1B (LCA) · WARN NOT HELD12. Labor
| Measure | Value | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|
| Employer name (as filed) | Century Therapeutics Inc. | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-20 11:15 UTC | Report an error |
| Certified LCAs | 1 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-20 11:15 UTC | Report an error |
| Certified LCAs later withdrawn | 1 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-20 11:15 UTC | Report an error |
| Total worker positions on certified LCAs | 1 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-20 11:15 UTC | Report an error |
| Top job titles (title, LCA count) | Associate Scientist, Discovery Biology (1) | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-20 11:15 UTC | Report an error |
| Wage offered, annualized (n, min, median, max) | median $120,000 (range $120,000-$120,000, 1 filings) | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-20 11:15 UTC | Report an error |
| Worksite states | MA | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-20 11:15 UTC | Report an error |
Unconfirmed: these labor figures (positions, worksite states, certified LCAs later withdrawn) are as read from DOL's quarterly LCA disclosure file. Seraphix's independent second check of them is not finished (11-19); they are shown as filed, not as verified.
WARN layoff notices: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
1 state and city record carry this company's exact name, from 1 source. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCentury Therapeutics, Inc. · exact legal name · sx:ctgov:h3b36f390f4d4c940 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1850119.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001850119. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.